CRISPR Therapeutics AG (LTS:0VRQ) Total Long-Term Assets: $277.46 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
34 GF Score
Price $47.60
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Total Long-Term Assets?

CRISPR Therapeutics AG LTS:0VRQ +1.02% 34 Total Long-Term Assets is $277.46 Mil as of Mar. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. CRISPR Therapeutics AG's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $277.46 Mil.

CRISPR Therapeutics AG Total Long-Term Assets Related Terms

CRISPR Therapeutics AG Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Total Long-Term Assets Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 334.36 390.03 321.49 304.90 279.57

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 298.49 296.05 316.22 279.57 277.46
LTS:0VRQ
34GF Score
CRISPR Therapeutics AG LTS:0VRQ
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $277.46 Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Total Long-Term Assets of $277.46 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Total Long-Term Assets too high?
CRISPR Therapeutics AG's current Total Long-Term Assets is $277.46 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Total Long-Term Assets compare to ORKA and TVTX?
CRISPR Therapeutics AG's Total Long-Term Assets of $277.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Total Long-Term Assets is $277.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
CRISPR Therapeutics AG (LTS:0VRQ) has a current Total Long-Term Assets of $277.46 Mil. The current Total Long-Term Assets is $277.46 Mil. CRISPR Therapeutics AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Total Long-Term Assets is $277.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
34GF Score

Get the complete analysis for LTS:0VRQ

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.60
Price